Comparative Pharmacology
Head-to-head clinical analysis: SEPHIENCE versus ZYPREXA ZYDIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEPHIENCE versus ZYPREXA ZYDIS.
SEPHIENCE vs ZYPREXA ZYDIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEPHIENCE (pegfilgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog. It binds to G-CSF receptors on hematopoietic cells, stimulating proliferation, differentiation, and release of neutrophils from bone marrow.
Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C receptors, dopamine D1-D4 receptors, muscarinic M1-M5 receptors, histamine H1 receptors, and alpha1-adrenergic receptors. Antagonism at D2 and 5-HT2A receptors is primarily responsible for its antipsychotic effects.
Adults: 200 mg orally twice daily with food.
10 mg orally once daily; range 5-20 mg once daily. Initial dose 5-10 mg, titrate by 5 mg weekly. Maximum 20 mg/day. Orally disintegrating tablet.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults, allowing for twice-daily dosing. Half-life may be prolonged in renal impairment (up to 30 hours in severe cases).
Terminal elimination half-life: ~30 hours (range 21–54 hours) in healthy adults; prolonged in elderly (mean 51.8 h) and hepatic impairment.
SEPHIENCE is primarily eliminated via renal excretion (approximately 70% as unchanged drug) and biliary/fecal excretion (approximately 25% as metabolites and unchanged drug).
Renal: ~57% (as metabolites); Fecal: ~30% (as metabolites); Unchanged olanzapine in urine <7%.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic